Hong Kong Construction Stock News

Shenwan Hongyuan (H.K.) came into these results with a flat 7 day share price and a muted 30 day slip, yet the latest numbers point to a business quietly grinding out profits. The stock closed at HK$0.965 on 26 August, while the headline from H1 2026 is simple: earnings stayed in the black and the trailing twelve month basic earnings per share reached HK$0.077766, putting the stock on a 12.4x P/E. For a capital markets broker that only recently turned profitable, the focus now is on how...

E-Commodities Holdings stock has been on a quiet tear, with double digit gains over the past month and quarter. Today, however, the real story is not the share price. The headline from this half year result is a sharp earnings punch, with basic earnings per share at HK$0.095 and net income of HK$250.361 million. For a low P/E stock trading around HK$0.775, that profit recovery is what long term holders will care about most. The short term price chart looks strong, but the bigger question now...

West China Cement stock closed at HK$2.03 after a choppy few months that included a 7 day gain and a weaker 90 day stretch. The headline from these H1 2026 numbers is profit compression. Basic earnings per share came in at C¥0.069 on revenue of C¥4,526.9m, with a trailing net margin of 5.8% compared with 9.8% a year earlier. Short term traders may focus on that squeeze. Longer term investors will be weighing it against forecasts for faster earnings and revenue growth, and a share price that...

Beijing Enterprises Urban Resources Group came into these results priced like a forgotten small cap, with the stock at HK$0.405 and only a flat month behind it. The market has treated this as a low‑expectation value story. The headline from H1 2026 is that profitability has held together, with basic earnings per share at CN¥0.0099 and net income of CN¥35.329m, even as revenue printed at CN¥3,132.432m. For a waste services operator that only recently turned profitable on a trailing basis, the...

TVB’s share price has drifted down in recent weeks, yet today’s earnings story is less about the chart and more about a pressure point on the income statement. The headline is a squeeze on profit in the first half of 2026, with revenue of HK$1,257.5m sitting alongside a net loss of HK$73.6m and a basic loss per share of HK$0.16. For a stock trading on an 11.4x P/E and already flagged for weak interest coverage, that mix of thin earnings support and financing strain is what is really driving...

Laekna shares closed at HK$6.26 on Wednesday, capping a choppy three months in which the stock has fallen sharply despite analysts pointing to very large implied upside. The H1 2026 earnings print sharpened that tension. The company is still loss making, yet the headline story this half is how small the loss has become relative to its revenue base. Laekna booked revenue of C¥150.3m in the first half of 2026 and reported a basic loss per share of C¥0.01, alongside a net loss of C¥2.5m. For a...

Long term Treasury yields around 4.73% on the 10 year and 5.27% on the 30 year have pushed bonds back into the spotlight, while the U.S. Treasury’s larger buybacks keep liquidity in focus without the comfort of full scale stimulus. For investors, that mix can reshuffle which stocks look attractive. This article explains the broader environment and then walks through three life and annuity insurers that are exposed to these dynamics. The three insurers covered below are only a starting sample,...

Ascentage Pharma Group International (SEHK:6855) updated investors with its half-year 2026 results, reporting CNY 302.21 million in sales and a net loss of CNY 816.69 million, along with wider basic and diluted loss per share. Ascentage Pharma Group International’s latest half year loss update comes after a period in which the share price has fallen 16.97% over 90 days and 34.62% year to date, contributing to a 60.14% decline in 1 year total shareholder return, despite a positive 3 year total...

Dekon Food and Agriculture Group (SEHK:2419) is in focus after its latest half year results showed sales of CNY 10,068.49 million and a shift from prior net income to a CNY 1,158.78 million net loss. The earnings release on 18 August comes after a tough stretch for Dekon Food and Agriculture Group’s shareholders, with the share price return down 24.96% year to date and the 1 year total shareholder return down 45.06% despite a modest 2.06% 3 month share price gain. This suggests any recent...

As global markets navigate a landscape marked by elevated Treasury yields, geopolitical tensions, and fluctuating energy prices, investor sentiment remains cautious. Amid these dynamics, the Asian market presents intriguing opportunities for those seeking to explore small-cap stocks that may offer promising potential in a complex economic environment. Identifying these gems requires an understanding of how companies might leverage regional economic trends and sector-specific growth drivers to...

Despite the fact that Canggang Railway Limited (HKG:2169) stock rose 15% last week, insiders who sold CN¥1.1b worth of...

Guangdong Join-Share Financing Guarantee Investment Co., Ltd.'s (HKG:1543) stock price has dropped 10% in the previous...

Flat Glass Group Co., Ltd. ( HKG:6865 ), might not be a large cap stock, but it saw a decent share price growth of 20...

Investors in China Hongqiao Group Limited ( HKG:1378 ) had a good week, as its shares rose 2.3% to close at HK$23.48...

It's been a good week for Jinxin Fertility Group Limited ( HKG:1951 ) shareholders, because the company has just...

China Petroleum & Chemical Corporation ( HKG:386 ) just released its latest half-yearly report and things are not...

As you might know, Shanghai Henlius Biotech, Inc. ( HKG:2696 ) recently reported its interim numbers. It was a...

Last week saw the newest half-year earnings release from China Resources Building Materials Technology Holdings Limited...

As of August 2026, Asian markets have been navigating a complex landscape marked by global economic uncertainties and fluctuating investor sentiment. Despite these challenges, opportunities for value investing persist, with certain stocks trading at a discount offering potential for growth in the long term. Identifying undervalued stocks involves looking for companies with strong fundamentals that remain resilient amid broader market volatility.

As global markets navigate a complex landscape marked by rising oil prices and geopolitical tensions, investors are increasingly turning their attention to opportunities in Asia. Penny stocks, though often seen as relics of past market eras, continue to capture interest due to their potential for growth and affordability. By focusing on companies with strong financial foundations, investors can uncover promising opportunities within this segment of the market.

Huaneng Power International (SEHK:902) reported half year 2026 results that showed lower revenue and net income compared with the same period in 2025. The earnings update appears to have influenced recent trading in the stock. See our latest analysis for Huaneng Power International. Since the earnings announcement on 18 August 2026, Huaneng Power International’s share price has been volatile, with the stock at HK$5.45 after a 1 day gain of 1.11% but a 90 day share price return that has fallen...

Investors in Xinyi Solar Holdings (SEHK:968) are assessing a fresh leadership shift after the company announced the retirement of executive director and financial controller Mr. Chu Charn Fai and the appointment of Mr. Lam Chi Kwong. See our latest analysis for Xinyi Solar Holdings. At a latest share price of HK$2.345, Xinyi Solar Holdings has seen a 1 month share price return of 11.14%, yet its year to date share price return is down 23.37% and the 5 year total shareholder return is down...

WuXi Biologics (Cayman) half year earnings in focus WuXi Biologics (Cayman) (SEHK:2269) reported half year 2026 earnings, noting higher sales, net income and earnings per share compared with the same period in 2025. See our latest analysis for WuXi Biologics (Cayman). Alongside these half year results, WuXi Biologics (Cayman) has seen strong recent momentum, with a 30 day share price return of 33.5% and a 90 day share price return of 54.99%, while the 1 year total shareholder return is...

HBM Holdings (SEHK:2142) is back in focus after Harbour BioMed received approval from China’s National Medical Products Administration for an Investigational New Drug application linked to HBM7004, a bispecific antibody targeting advanced solid tumors. See our latest analysis for HBM Holdings. The HBM7004 IND approval arrives as HBM Holdings trades at HK$16.54, with a 30-day share price return of 32.21% and a 90-day share price return of 40.77%, while the 3-year total shareholder return is...